Please ensure Javascript is enabled for purposes of website accessibility

GoodRx to Take Its $2.8 Billion Drug Coupon Business Public

By Cory Renauer – Updated Sep 1, 2020 at 6:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company that helps consumers find deals on prescription drugs is surprisingly profitable.

An increasingly popular provider of prescription drug coupons is taking itself public soon. GoodRx is preparing for an initial public offering, and the financial disclosures are turning a lot of heads.

GoodRx had been looking for a buyer until a private equity firm, Silver Lake, raised its equity stake in the company to 37% earlier this month. The company filed its prospectus quietly on Aug. 29, without mentioning pricing or how many shares will be offered.

A pharmacist stocking shelves.

Image source: Getty Images.

GoodRx earns money from pharmacy benefits managers every time a consumer uses a GoodRx code to fill a prescription. Last September, GoodRx acquired HeyDoctor, a telehealth services provider, but revenue from its prescription drug services still represents 91% of the company's top line. 

Flush with cash from its upcoming IPO, GOODRx could begin to pressure Teladoc Health (TDOC 1.81%) by routing consumers to competing telehealth options. GoodRx's Telehealth Marketplace is already duplicating its prescription drug discount code service with physician visits.

You might not expect significant profits from a company that earns nearly all its money providing discount codes at no cost to consumers upfront, but the prospectus GoodRx presented investors suggests the company has carved out an extremely lucrative niche in America's convoluted market for prescription drugs. In 2019 the company produced a $139 million operating profit from just $388 million in top-line revenue. 

Since its inception in 2011, GoodRx had been growing by leaps and bounds until COVID-19-related lockdowns put a crimp on pharmacy sales in general. The company recorded 4.9 million monthly active users during the first three months of 2020, a 53% increase over the previous year period. Unfortunately, pandemic-related pressure pushed the average number of monthly active users down to 4.4 million during the three-month period ended Jun. 30, 2020.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$26.90 (1.81%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.